These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Unravelling benzazepines and aminopyrimidine as multi-target therapeutic repurposing drugs for EGFR V774M mutation in neuroglioma patients. Singh J; Khanduja KL; Avti PK Bioimpacts; 2024; 14(3):28876. PubMed ID: 38938756 [TBL] [Abstract][Full Text] [Related]
43. A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism. Lage-Rupprecht V; Schultz B; Dick J; Namysl M; Zaliani A; Gebel S; Pless O; Reinshagen J; Ellinger B; Ebeling C; Esser A; Jacobs M; Claussen C; Hofmann-Apitius M Patterns (N Y); 2022 Mar; 3(3):100433. PubMed ID: 35510183 [TBL] [Abstract][Full Text] [Related]
44. Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles. Ahmed F; Ho SG; Samantasinghar A; Memon FH; Rahim CSA; Soomro AM; Pratibha ; Sunildutt N; Kim KH; Choi KH Comput Struct Biotechnol J; 2022; 20():6097-6107. PubMed ID: 36420161 [TBL] [Abstract][Full Text] [Related]
45. Drugsniffer: An Open Source Workflow for Virtually Screening Billions of Molecules for Binding Affinity to Protein Targets. Venkatraman V; Colligan TH; Lesica GT; Olson DR; Gaiser J; Copeland CJ; Wheeler TJ; Roy A Front Pharmacol; 2022; 13():874746. PubMed ID: 35559261 [TBL] [Abstract][Full Text] [Related]
46. Drug Repurposing: a Shortcut to New Biological Entities. Rao N; Poojari T; Poojary C; Sande R; Sawant S Pharm Chem J; 2022; 56(9):1203-1214. PubMed ID: 36531825 [TBL] [Abstract][Full Text] [Related]
47. Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Daina A; Zoete V Commun Chem; 2024 May; 7(1):105. PubMed ID: 38724725 [TBL] [Abstract][Full Text] [Related]
48. Brief considerations on targeting RNA with small molecules. Vicens Q; Westhof E Fac Rev; 2022; 11():39. PubMed ID: 36644293 [TBL] [Abstract][Full Text] [Related]
49. Editorial: Anti-inflammatory drug development focusing on immune mediated diseases. Oliveira-Costa JF; Prasad A Front Pharmacol; 2024; 15():1413141. PubMed ID: 38828448 [No Abstract] [Full Text] [Related]
51. Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery. Rudrapal M; Paudel KR; Pangeni R Front Pharmacol; 2022; 13():1101007. PubMed ID: 36605397 [No Abstract] [Full Text] [Related]
52. Glycoprotein attachment with host cell surface receptor ephrin B2 and B3 in mediating entry of nipah and hendra virus: a computational investigation. Priyadarsinee L; Sarma H; Sastry GN J Chem Sci (Bangalore); 2022; 134(4):114. PubMed ID: 36465097 [TBL] [Abstract][Full Text] [Related]
53. Computational screening for investigating the synergistic regulatory potential of drugs and phytochemicals in combination with 2-deoxy-D-glucose against SARS-CoV-2. Gupta A; Chauhan SS; Gaur AS; Parthasarathi R Struct Chem; 2022; 33(6):2179-2193. PubMed ID: 36093277 [TBL] [Abstract][Full Text] [Related]
54. Applying polypharmacology approach for drug repurposing for SARS-CoV2. Jamir E; Sarma H; Priyadarsinee L; Nagamani S; Kiewhuo K; Gaur AS; Rawal RK; Murugan NA; Subramanian V; Sastry GN J Chem Sci (Bangalore); 2022; 134(2):57. PubMed ID: 35498548 [TBL] [Abstract][Full Text] [Related]